Drug Profile
JNJ 64417184
Alternative Names: JNJ-64417184Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Alios BioPharma
- Developer Alios BioPharma; Janssen Research & Development
- Class Antivirals
- Mechanism of Action Polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections in Germany (PO, Tablet)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in Belgium (PO, Tablet)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in Netherlands (PO, Tablet)